Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (126)	6/28/2000 7:35:00 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

David, I grabbed a Globe and here are some quotes: "We view this as extremely positive," analyst Brian Bapty of Goepel McDermid Inc. said in a research report. He "strongly" reiterated his "buy" recommendation on the stock, with a near-term price range of $13.50 to $23.50. (these are all Canadian dollars). In another new report, Christine Charette of BMO Nesbitt Burns Inc. said the Phase II study is the "first indication that HspE7 has met its proof of concept and has a good chance of becoming a drug." She figures the drug could be on the market as early as late 2002 or early 2003, provided test results continue to be encouraging. StressGen said it is hoping to report Phase II study results at a medical conference in Spain at the end of July, or at another conference in October. "In advance of this trial data, we believe healthy speculation is warranted and that in the near term, StressGen could easily obtain a $1-billion market capitalization, representing $23.50 per share," Mr. Bapty said. "HspE7 is poised to enter a multibillion-dollar market with little or no therapeutic competition," Mr. Bapty said, adding that the drug is "validating a technique that could be extended to a host of other diseases." Based on conservative forecasts to treat anal and cervical dysplasia, Mr. Bapty figures StressGen could be in line for annual royalties in the order of $65-million by the third year of sales. Treating genital warts could add another 30 per cent to these sales estimates, he added. Of course, we must keep in mind these quotes are from people who work at companies who stand to benefit greatly from any StressGen success. Nevertheless, it's the right sort of stuff to be hearing. Heat